Molecular Fluorescence Endoscopy of (Pre)Malignant Esophageal Lesions

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 9, 2017

Primary Completion Date

March 25, 2019

Study Completion Date

September 1, 2019

Conditions
Barrett EsophagusEsophageal CancerDysplasia in Barrett Esophagus
Interventions
DRUG

IV-administation of EMI-137

Intravenous administration of 0.13 mg/kg of the fluorescent tracer EMI-137 approximately 2.5 hours prior to the endoscopy procedure.

DEVICE

Molecular Fluorescence Endoscopy platform

A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working-channel of the standard clinical endoscope. Fluorescence imaging will be performed prior to and post the endoscopic resection, during the same endoscopy procedure.

Trial Locations (1)

9713GZ

University Medical Center Groningen, Groningen

All Listed Sponsors
lead

University Medical Center Groningen

OTHER

NCT03205501 - Molecular Fluorescence Endoscopy of (Pre)Malignant Esophageal Lesions | Biotech Hunter | Biotech Hunter